Literature DB >> 22398467

Completion pneumonectomy: a multicentre international study on 165 patients.

Giuseppe Cardillo1, Domenico Galetta, Paul van Schil, Andrea Zuin, Pierluigi Filosso, Robert J Cerfolio, Anna Rita Forcione, Francesco Carleo.   

Abstract

OBJECTIVES: We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP).
METHODS: A retrospective review of a consecutive series of patients who underwent CP at six international centres.
RESULTS: In total, 165 CP were performed between March 1990 and December 2009: 152 for malignant disease and 13 for benign disease. Forty-two patients (25.4%) underwent neoadjuvant therapy. Right CP was performed in 99 patients (60%) and left in 66 (40%). Thoracotomy was employed in 161 patients and median sternotomy in 4. Stapled closure of the bronchus was performed in 121 patients and hand closure in 44. The overall operative mortality was 10.3% (17 of 165). Operative mortality was 10.5% (16 of 152) in malignant diseases and 7.7% (1 of 13) in benign diseases. Complications occurred in 55.1% (91 of 165) of patients. Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9%) developed bronchopleural fistulas. No statistically significant relationship was found in mortality or morbidity according to side, gender, induction therapy and surgical approach. Stapled compared with hand closure for the bronchus did not affect the bronchopleural fistula rate (P = 0.4). The overall 5-year survival was 37.6%: 70.1% in benign disease (13 patients), 48.9% in squamous cell carcinoma of the lung (63 patients), 23.9% in primary lung adenocarcinoma (62 patients), 50% in grade 1 and grade 2 neuroendocrine carcinoma of the lung (4 patients), 54.7% in metastatic disease (14 patients) and 0% in primary lung sarcomas. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04).
CONCLUSIONS: CP shows an acceptable operative mortality with a high morbidity rate. The overall 5-year survival is acceptable in properly selected patients (i.e. squamous cell carcinoma, metastatic disease). Side, gender, induction therapy and surgical approach did not influence mortality and morbidity.

Entities:  

Mesh:

Year:  2012        PMID: 22398467     DOI: 10.1093/ejcts/ezs063

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Completion pneumonectomy: outcomes for benign and malignant indications.

Authors:  Varun Puri; Andrew Tran; Jennifer M Bell; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2013-05-03       Impact factor: 4.330

2.  Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries.

Authors:  Dragan Subotic; Laureano Molins; Ivan Soldatovic; Dejan Moskovljevic; Lucia Collado; Jorge Hernández
Journal:  World J Surg Oncol       Date:  2018-05-28       Impact factor: 2.754

3.  Iterative surgical resections in non-small cell lung cancer.

Authors:  Ahmet Ucvet; Serkan Yazgan; Ozgur Samancilar; Soner Gursoy; Ahmet Emin Erbaycu; Berna Komurcuoglu
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-01-09

4.  Completion Pneumonectomy for Non-Small-Cell Lung Cancer: Does Induction Treatment Influence Postoperative Outcomes?

Authors:  Domenico Galetta; Lorenzo Spaggiari
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

5.  The technique of stump closure has no impact on post-pneumonectomy bronchopleural fistula in the non-small cell lung cancer-a cross-sectional study.

Authors:  Piotr Skrzypczak; Magdalena Roszak; Mariusz Kasprzyk; Wojciech Dyszkiewicz; Mikołaj Kamiński; Piotr Gabryel; Cezary Piwkowski
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

6.  Completion pneumonectomy: Indications and outcomes in non-small cell lung cancer.

Authors:  Serkan Yazgan; Ahmet Üçvet; Soner Gürsoy; Özgür Samancılar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-09-16       Impact factor: 0.332

7.  Completion pneumonectomy and chemoradiotherapy as treatment options in local recurrence of non-small-cell lung cancer.

Authors:  Mariusz Kasprzyk; Grzegorz Sławiński; Martyna Musik; Łukasz Marciniak; Wojciech Dyszkiewicz; Cezary Piwkowski; Bartłomiej Gałęcki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-03-31

8.  A case report: right upper lobectomy with middle lobe preservation after right lower lobectomy.

Authors:  Hitoshi Igai; Mitsuhiro Kamiyoshihara; Natsuko Kawatani; Takashi Ibe; Kimihiro Shimizu
Journal:  Surg Case Rep       Date:  2015-02-19

9.  Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer.

Authors:  Abby White; Suden Kucukak; Daniel N Lee; Raphael Bueno; Michael Jaklitsch; Steven Mentzer; David Sugarbaker; Jon Wee; Scott J Swanson
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.